EirGenix Inc (台康生技), a contract development and manufacturing organization (CDMO) and biosimilars maker, yesterday said it expects to begin the global phase III trial for its Herceptin (trastuzumab) biosimilar EG12014 in the second quarter of next year at the earliest.
“We have successfully completed four batches of 1,000 liters of EG12014 this year, as part of preparations for the phase III trial,” EirGenix president and CEO Liu Lee-cheng (劉理成) told an investors’ conference.
EirGenix was spun off from the Development Center for Biotechnology in December 2012 and officially registered as a new company in March 2013 with a paid-in capital of NT$540 million (US$17.98 million at the current exchange rate).
The company has two main business units: CDMO and product development, which includes the development of biosimilars, specialty biologics and novel biologics, Liu said.
EirGenix has seven product lines, four of which are biosimilars, he said, adding that the development of EG12014 is progressing faster than the company’s other biosimlars.
After a comprehensive similarity assessment, EG12014 was found to be highly similar to Herceptin at all tested scales, and across all structural and functional tests, Liu said.
Herceptin is used to treat breast or metastatic stomach cancers.
The global phase III trial is to cost between 50 million and 60 million euros (US$58.8 million and US$70.5 million) and is to involve 800 patients in 20 nations, he said.
Due to the sizeable costs of the trial, EirGenix is in talks with five potential strategic partners to share the expense, and to market and sell the product when it is commercialized, he added.
“Two of the five potential partners have entered the critical negotiation stage with EirGenix,” Liu said. “We hope to strike a deal with one of them soon.”
Chang Chih-jung (張志榮), vice president of EirGenix’s CDMO unit, said the company’s CDMO business broke even in the first half of this year and turned profitable last quarter.
Revenue from EirGenix’s overseas clients accounted for nearly 40 percent of the firm’s total revenue in the first three quarters of the year, he said, adding that the company expects the revenue contribution from overseas clients to reach 50 percent next year.
EirGenix estimated that revenue from the CDMO unit would continue to grow by a double-digit percentage next year on the back of newly added clients in China, the US and Europe, Chang said.
The firm’s new plant in Hsinchu County’s Jhubei City (竹北市) is to become operational next year to support the CDMO unit’s growing orders, he added.
The company reported net losses of NT$94.75 million in the first half of the year, compared with net losses of NT$40.08 million in the same period last year, a filing with the Taiwan Stock Exchange showed.
The firm has not yet reported its earnings performance for last quarter.
WASHINGTON’S INCENTIVES: The CHIPS Act set aside US$39 billion in direct grants to persuade the world’s top semiconductor companies to make chips on US soil The US plans to award more than US$6 billion to Samsung Electronics Co, helping the chipmaker expand beyond a project in Texas it has already announced, people familiar with the matter said. The money from the 2022 CHIPS and Science Act would be one of several major awards that the US Department of Commerce is expected to announce in the coming weeks, including a grant of more than US$5 billion to Samsung’s rival, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), people familiar with the plans said. The people spoke on condition of anonymity in advance of the official announcements. The federal funding for
HIGH DEMAND: The firm has strong capabilities of providing key components including liquid cooling technology needed for AI servers, chairman Young Liu said Hon Hai Precision Industry Co (鴻海精密) yesterday revised its revenue outlook for this year to “significant” growth from a “neutral” view forecast five months ago, due to strong demand for artificial intelligence (AI) servers from cloud service providers. Hon Hai, a major assembler of iPhones that is also known as Foxconn, expects AI server revenues to soar more than 40 percent annually this year, chairman Young Liu (劉揚偉) told investors. The robust growth would uplift revenue contribution from AI servers to 40 percent of the company’s overall server revenue this year, from 30 percent last year, Liu said. In the three-year period
LONG HAUL: Largan Energy Materials’ TNO-based lithium-ion batteries are expected to charge in five minutes and last about 20 years, far surpassing conventional technology Largan Precision Co (大立光) has formed a joint venture with the Industrial Technology Research Institute (ITRI, 工研院) to produce fast-charging, long-life lithium-ion batteries for electric vehicles, mobile electronics and electric storage units, the camera lens supplier for Apple Inc’s iPhones said yesterday. Largan Energy Materials Co (萬溢能源材料), established in January, is developing high-energy, fast-charging, long-life lithium-ion batteries using titanium niobium oxide (TNO) anodes, it said. TNO-based batteries can be fully charged in five minutes and have a lifespan of 20 years, a major advantage over the two to four hours of charging time needed for conventional graphite-anode-based batteries, Largan said in a
Taiwan is one of the first countries to benefit from the artificial intelligence (AI) boom, but because that is largely down to a single company it also represents a risk, former Google Taiwan managing director Chien Lee-feng (簡立峰) said at an AI forum in Taipei yesterday. Speaking at the forum on how generative AI can generate possibilities for all walks of life, Chien said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) — currently among the world’s 10 most-valuable companies due to continued optimism about AI — ensures Taiwan is one of the economies to benefit most from AI. “This is because AI is